APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned

EQS-News: APONTIS PHARMA AG / Key word(s): Annual Report/Annual Results
APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned
31.03.2025 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned

• Sales increases significantly to EUR 48.5 million in 2024 financial year (2023: EUR 37.0 million)
• Strong increase in Single Pill combination revenues to EUR 34.4 million (2023: EUR 25.6 million)
• EBITDA increases by EUR 16.8 million to EUR 3.5 million (2023: EUR -13.3 million)
• Squeeze-out and merger with Zentiva AG planned

Monheim / Rhein, 31 March 2025. Die APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company for Single Pill combinations in Germany, closed the 2024 financial year with a significant increase in sales of 31.1% to EUR 48.5 million (2023: EUR 37.0 million). EBITDA in the reporting period improved significantly by EUR 16.8 million from EUR 13.3 million to EUR 3.5 million, confirming the realignment of strategy and go-to-market initiated in 2023 and the cost reductions realized here.

“The significant increase in sales and earnings demonstrates the success of our reorganization of APONTIS PHARMA. We have fundamentally optimized sales, revised our go-to-market approach and significantly reduced costs. Accordingly, the success is reflected both in sales and disproportionately in earnings. The acquisition offer from Zentiva is a confirmation of this strategy. Zentiva recently announced that it is seeking a squeeze-out and a merger with Zentiva AG. The success story of the Single Pill combinations will therefore continue under a new umbrella,” said Bruno Wohlschlegel, CEO of APONTIS PHARMA.

Significant growth in all segments

Sales of EUR 48.5 million generated in the 2024 financial year were only slightly below the forecast of EUR 50.0 million. Single Pill combinations revenue increased significantly from EUR 25.6 million to EUR 34.4 million. This was attributable in particular to the improved supply situation for Atorimib (from EUR 8.8 million to EUR 16.7 million) and the growth of the remaining Single Pills excluding Atorimib, Caramlo and Tonotec, whose sales increased by EUR 2.8 million. The new go-to-market-concept introduced in spring 2024 had a noticeable impact here.

Sales in the cooperation business increased by 36% to EUR 12.6 million in the financial year (2023: EUR 9.3 million). The agreement concluded with Novartis in April 2024 for the two asthma products Atectura and Enerzair made a significant contribution to this. Sales of EUR 9.0 million were already generated in the first nine months of distribution.

Thomas Milz, CPO of APONTIS PHARMA: “Both the Single Pill combinations (including four new launches in 2024) and the cooperation business delivered in the past financial year and each contributed significantly to the increase in sales. The improved availability of our bestseller Atorimib and, of course, the new go-to-market approach also helped. Thanks to APONTIS PHARMA, Single Pill combinations are now established on the market, as they have considerable advantages over loose combinations in terms of adherence and contribute to better healthcare.”

Increase in profitability

The positive development of sales and cost reductions had a disproportionately high impact on earnings. EBITDA rose to EUR 3.5 million, compared to EUR -13.3 million in the previous year. The previous year’s EBITDA was characterized by one-off restructuring expenses of EUR 5.6 million.

The cost of materials increased from EUR 13.8 million to EUR 20.8 million in line with the rise in sales. The increase in the cost of materials ratio to 42.8% (2023: 37.3%) was mainly due to the cooperation agreement concluded with Novartis for the products Atectura and Enerzair.

Personnel expenses amounted to EUR 13.5 million in the financial year (2023: EUR 24.6 million). In the previous year, restructuring costs of EUR 5.6 million were incurred, which were reported under personnel expenses.

APONTIS PHARMA closed the 2024 financial year with a consolidated net profit of EUR 0.8 million, following a consolidated net loss of EUR 11.3 million in the previous year.

APONTIS PHARMA’s equity amounted to EUR 31.0 million as of 31 December 2024 (2023: EUR 30.3 million), which corresponds to an equity ratio of 69.9% (2023: 52.7%). The increase is the result of the profit for the financial year and a lower balance sheet total.

“With very pleasing financial development figures and a solid balance sheet, APONTIS PHARMA is expected to leave the stock exchange in the coming months. The business model has proven to be solid and will continue to gain momentum under the Zentiva umbrella and take the step towards European expansion,” added Thomas Zimmermann, CFO of APONTIS PHARMA.

Continuation of growth course

APONTIS PHARMA intends to continue on its growth path in the 2025 financial year. The Single Pill business is expected to continue to grow in the 2025 financial year. This will mainly be achieved through the existing Single Pill portfolio and the effects of the planned new launches in 2025. APONTIS PHARMA currently expects two new launches to take place in the current financial year. The cooperation business will grow overall due to the cooperation with Novartis entered into in April 2024.

APONTIS PHARMA expects sales to increase by 16% to EUR 56.4 million in the 2025 financial year (2024: EUR 48.5 million). The Company expects EBITDA to increase from EUR 3.5 million to EUR 4.5 million.

Voluntary public purchase offer by Zentiva and squeeze-out under merger law

On 24 October 2024, the pharmaceutical group Zentiva published a purchase offer for shares in APONTIS PHARMA AG. Zentiva now holds around 93.83% of the Company’s share capital and is therefore the majority shareholder. On 5 March, Zentiva submitted a request to APONTIS PHARMA pursuant to Section 62 (1) and (5) UmwG (German Reorganization Act) in conjunction with Sections 327a et seq. AktG (German Stock Corporation Act), according to which a merger agreement is to be concluded between the Company and Zentiva AG and the Annual General Meeting of APONTIS PHARMA is to resolve on the transfer of the shares of the remaining shareholders (minority shareholders) to Zentiva as the majority shareholder in return for the granting of appropriate cash compensation (so-called squeeze-out under merger law).

APONTIS PHARMA will provide information about the date of the Annual General Meeting at which a corresponding transfer resolution is to be passed in accordance with the statutory requirements.

Group figures

Note: Rounding differences may occur.

Condensed Group Income Statement

Note: Rounding differences may occur.

Condensed Consolidated Statement of Financial Position

Note: Rounding differences may occur.

Condensed Group Statement of Cash Flows

Note: Rounding differences may occur.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pill combinations in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. Single Pill therapies have been scientifically proven to significantly increase adherence and thus improve the treatment prognosis and quality of life of patients while reducing complications, mortality, and treatment costs. Consequently, Single Pill combinations are the preferred treatment option in numerous international treatment guidelines, including in the EU and Germany. APONTIS PHARMA has been developing, promoting, and distributing a broad portfolio of Single Pill combinations and other pharmaceutical products since 2013, with a special focus on cardiovascular diseases such as hypertension, hyperlipidemia, and secondary prevention. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Rolf-Schwarz-Schütte Platz 1
40789 Monheim / Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Press Contact
CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330

Disclaimer – Legal notice

The information contained in this press release may include certain forward-looking statements that are based on current assumptions and forecasts made by the management of APONTIS PHARMA AG. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Such factors include those discussed in APONTIS PHARMA AG’s public reports. These reports are available on www.apontis-pharma.de. The Company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.

31.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com